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9ABBREVIATIONS
ALT argon laser trabeculoplasty
ARM age-related macular degeneration
BCVA best-corrected visual acuity
CCC continuous curvilinear capsulorhexis
CG capsular glaucoma
D dioptre
ECCE IOL extracapsular cataract extraction and intraocular lens
implantation
EG exfoliation glaucoma
EXF exfoliation
GLT Glaucoma Laser Trial
IA infusion-aspiration
ICCE intracapsular cataract extraction
IOL intraocular lens
IOP intraocular pressure
LEC lens epithelial cell
Nd:YAG neodymium:yttrium aluminium garnet
OAG open-angle glaucoma
PC posterior chamber
PC-IOL posterior chamber IOL
PCO posterior capsular opacification
PHACO IOL phacoemulsification and intraocular lens implantation
PMMA poly(methyl methacrylate)
POAG primary open-angle glaucoma
SD standard deviation
SG simple glaucoma
TM trabecular meshwork
VA visual acuity
WHO World Health Organization
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ABSTRACT
Several consecutive series of 103 eyes undergoing extracapsular cataract
extraction and intraocular lens implantation (ECCE IOL) during 1985-1986 and 230
eyes undergoing phacoemulsification and intraocular lens implantation (PHACO
IOL) during 1995-1996 were enrolled in these studies to evaluate the effect of pure
cataract surgery on early and long-term intraocular pressure (IOP), occurrence of
complications and postoperative visual outcome in open-angle glaucoma (OAG)
and in nonglaucomatous eyes. Other subsidiary aims were to examine the effect of
preoperative argon laser trabeculoplasty (ALT) on postoperative IOP 0.5-3 years
after cataract surgery and to study posterior capsular opacification (PCO) with 2
different IOL types 1-2.4 years postoperatively.
In OAG eyes complications during surgery were more common with the ECCE than
PHACO technique (posterior capsule rupture with vitreous loss in 4.7% vs. 0% and
without vitreous loss in 4.7% vs. 2.6%). A low incidence of complications with the
PHACO technique was found both in OAG and nonglaucomatous eyes.
Preoperatively, 5% of OAG eyes in the ECCE group had visual acuity (VA) > 0.4
compared with 16% of OAG eyes and 22% of nonglaucomatous eyes in the
PHACO groups. Almost half (40%) the eyes in the ECCE group were blind
according to the World Health Organization (WHO) definition, whereas about 20%
of the eyes in the PHACO groups (OAG and nonglaucomatous eyes) were blind at
this stage. After a 1-3.6-year follow-up, 33% of the patients in the ECCE group and
39-55% of the patients in the PHACO groups had VA of 0.8 or better (after 1-3.7
years in OAG and after 1-2.7 years in nonglaucomatous eyes). A total of 25% of the
eyes in the ECCE group and 33-48% of the eyes in the PHACO groups had VA of
0.4-0.7. In the ECCE group, 33% of the OAG eyes showed VA of 0.05-0.3, and 9%
were blind. In 4/6 eyes blindness was related to glaucoma or postoperative IOP
rise. In the PHACO series, 10% of both OAG and nonglaucomatous eyes showed
VA of 0.05-0.3, and 3% and 2%, respectively, were blind. In both OAG and
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nonglaucomatous eyes blindness was related to the presence of age-related
macular degeneration (ARM) in all cases.
Postoperative early IOP exceeded 30 mmHg in 30% of OAG eyes in the ECCE
group and in 40% of the eyes in the PHACO group. In nonglaucomatous eyes the
rise in IOP was less common: 17% for EXF and 6% for non-EXF eyes. At the latest
control examination, the mean IOP decrease was 6% for primary open-angle
glaucoma (POAG) and 7% for exfoliation glaucoma (EG) eyes in the ECCE group.
After PHACO surgery the corresponding figures were greater: 13% for POAG and
21% for EG. In nonglaucomatous eyes the decrease was 20% after PHACO.
In OAG eyes the need for glaucoma medication decreased; 19% of POAG and
36% of EG eyes managed without medication after ECCE surgery and 17% of
POAG eyes and 12% of EG eyes after PHACO surgery, respectively. Medication
had to be increased in about 10% of the eyes both after ECCE and PHACO
surgery. In nonglaucomatous eyes 1 non-EXF eye was diagnosed with OAG 2
years after PHACO.
To study the effect of preoperative ALT on IOP after ECCE cataract surgery, 26
ALT-treated eyes were compared with 26 nonlaser-treated eyes. From 0.5 to 3
years after cataract surgery, the mean IOP decreased significantly in ALT but not
in the nonlaser-treated group. In the nonlaser-treated group the need for
medication was, however, significantly reduced. Most of the eyes in both groups
managed with less and 30% of the eyes with no medication. Medication had to be
increased in 8% of the ALT-treated and in 15% of the nontreated eyes. These
results indicate that the successful effect of ALT on IOP was not eliminated by
cataract surgery.
To study postoperative PCO, 80 consecutive eyes undergoing PHACO surgery for
cataract in 1995 were prospectively randomized into 2 groups, one receiving
silicone IOL and the other acrylic IOL. At 1-2.4 years postoperatively 25% of the
silicone IOL eyes and 19% of the eyes in the acrylic group had developed clinically
significant PCO. The difference between the groups was not significant.
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In summation, complications were more common during ECCE surgery than with
PHACO surgery. Indications for cataract surgery have changed, and PHACO
surgery was performed at an earlier stage with better preoperative VA.
Postoperative VA results were better after PHACO than ECCE surgery, and the
results in OAG and nonglaucomatous eyes after PHACO surgery were
comparable. Early postoperative IOP rise in OAG eyes was more common after
PHACO than ECCE surgery, but no cases of blindness caused by postoperative
pressure rise were found after PHACO surgery. Long-term reduction of IOP
compared with the preoperative level was statistically significant after both ECCE
and PHACO in all study groups (POAG, EG and nonglaucomatous eyes). The
pressure reduction was 6-7% after ECCE and 13-21% after PHACO in POAG vs.
EG eyes and 21-23% in nonglaucomatous non-EXF vs. EXF eyes. After cataract
surgery glaucoma medication could be reduced, and after ECCE 19-36% of eyes
and after PHACO 12-17% of eyes managed without medication. In contrast,
glaucoma medication had to be increased during the follow-up in about 10% of the
eyes. In conclusion, cataract surgery in OAG results in significant long-term IOP
reduction with less medication in most of the patients. In eyes with simultaneous
OAG and cataract, pure cataract surgery may be sufficient to maintain IOP
controlled with or without glaucoma medication.
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1. INTRODUCTION
Glaucoma and cataract are common disorders in the elderly, and the prevalence of
both increases with age. In Finland about 60 000 people suffer from glaucoma, and
yearly more than 35 000 cataract operations are performed in our country. Many
elderly persons have both glaucoma and cataract, but the exact number of patients
with combined disease is not known, nor do we know how many cataract operations
are performed on glaucomatous eyes.
In Finland exfoliation (EXF) syndrome is closely related to both glaucoma and
cataract. More than 20% of persons 60 years of age or older (Krause et al. 1973,
and others), about half of eyes with open-angle glaucoma (OAG) (Lindberg 1917,
and others) and about one third of eyes undergoing cataract surgery (Hietanen et
al. 1992, Lumme & Laatikainen 1993) have EXF syndrome. Surgery for EXF
cataract and combined cataract and glaucoma is more complicated than for pure
cataract, and the various effects of surgery on these eyes may differ from those in
non-EXF eyes.
Remarkable development in cataract surgery techniques during the last 10-20
years has improved results and decreased the risks of surgery, but not all
complications can as yet be avoided. To decrease the risk of complications in
glaucomatous eyes, it is important to decrease the intraocular pressure (IOP) to
normal level before surgery either by medication, argon laser trabeculoplasty (ALT)
or by surgical means. One of the most common problems occurring after cataract
surgery is posterior capsular opacification (PCO) with subsequent visual
deterioration. It may be treated with neodymium:yttrium aluminium garnet (Nd:YAG)
capsulotomy, but the treatment is not always harmless. Various efforts have
focused on preventing PCO. In the present study 2 types of intraocular lens (IOL)
were compared in this respect.
Management of coexisting glaucoma and cataract has been debated for years. The
following options are the currently preferred methods of choice: 1) cataract surgery
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first followed by glaucoma surgery if needed, 2) glaucoma surgery first followed by
cataract surgery or 3) combined cataract-glaucoma surgery.
The main aim of this study was to evaluate and compare the effect of pure cataract
surgery, using various techniques on the IOP level in primary open-angle
glaucoma (POAG), exfoliation glaucoma (EG) and nonglaucomatous eyes. In
addition, changes in the level of preoperative visual impairment, occurrence of
complications and postoperative visual outcome as well as PCO with 2 types of IOL
were compared.
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2. REVIEW OF THE LITERATURE
2.1 CATARACT AND GLAUCOMA
2.1.1 Prevalence of glaucoma
In the Framingham study (Kahn & Milton 1980), which included individuals 52-85
years of age, the prevalence of OAG was 1.4%. In Beaver Dam (Klein et al. 1992),
2.1% of those 43-84 years of age had OAG. In Roscommon (Coffey et al. 1993),
the prevalence was 2% of those over the age of 50, and a prevalence of 1.1%
among those 55 years or more of age was found in Rotterdam (Dielemans et al.
1994). In Sweden, Bengtsson (1981) reported 0.93% for the Dalby survey, which
spanned the age range of 57-71 years. In the Baltimore Eye Survey (Tielsch &
Javitt 1991), the adjusted prevalences among persons 40 years of age or more
were 4.7% for blacks and 1.3% for whites. In all these studies, the younger age limit
is low (40-55 years), which may explain the low prevalence figures. The prevalence
of glaucoma increases, however, with age and in the Nordic countries appears to
be higher. The highest figures were presented by Ringvold et al. (1991), who found
OAG in 8.3% of persons 64 years of age or older and Hirvelä et al. (1995) who
reported a 12% prevalence of glaucoma in a Finnish population-based study on
500 persons 70 years of age or older. In the latter study, 8% of the persons were
known to have glaucoma and another 4% showed optic disc changes typical for
glaucoma. In Finland, about 60 000 patients are entitled to special refund for
glaucoma medication (Lääkelaitos ja Kansaneläkelaitos - National Agency for
Medicines and Social Insurance Institution 1999). Of these patients, 79% are 65
years of age or older (72% female, 28% male; Kansaneläkelaitos - Social
Insurance Institution 2000).
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2.1.2 Exfoliation in eyes with or without glaucoma
In Northern Europe, the prevalence of EXF syndrome in elderly persons is high. In
Finland, prevalences of 21-22% in elderly people have been reported in several
studies (Krause et al. 1973, Hirvelä et al. 1995), and the prevalence increases with
age: from 14% in the 60-70-year age-groups to 30% or more in the 80-year or
older group (Krause et al. 1988). In OAG patients, prevalence rates for EXF
ranging from 48% to 60% have been found (Tarkkanen 1962, Ringvold et al. 1991,
Hirvelä et al. 1995), whereas in the USA less than 10% of patients with OAG have
been reported to have EXF syndrome (Ball 1988, Cashwell & Shields 1988).
Correspondingly, in Finland the prevalence of EXF is high in cataract patients.
About 30% of eyes undergoing cataract surgery and almost half of cataract patients
80 years of age or older have EXF syndrome (Hietanen et al. 1992, Lumme &
Laatikainen 1993).
EXF actively involves all tissues of the anterior segment of the eye and thus may
lead to a large variety of complications (Naumann et al. 1988, Ritch et al. 1996). In
the pathogenesis of EG degeneration of the ciliary epithelium is typical, and
aqueous secretion is thought to be impaired (Morrison & Green 1988). The exact
role of pigment and EXF deposits in the chamber angle in elevating IOP continues
to be debated (Layden et al. 1990, Puska 1995, Gottanka et al. 1997, Tarkkanen &
Kivelä 1999). The role of EXF fibres found in the walls of the posterior ciliary
arteries has not been studied systematically (Vesti & Kivelä 2000). According to
the hypothesis of Küchle et al. (2000), zonular weakness in the EXF syndrome
leads to anterior movement of the lens. Zonular instability is frequently associated
with EXF syndrome and may lead to intraoperative complications during cataract
surgery, most notably zonular dialysis and vitreous loss (Raitta & Setälä 1986,
Tarkkanen 1986, Skuta et al. 1987, Naumann et al. 1988, Kirkpatrick & Harrad
1992, Zetterström et al. 1992, Osher et al. 1993, Ritch 1996, Avramides et al. 1997,
Chitkara & Smerdon 1997, Goder 1998). Reduced anterior chamber depth may
indicate the presence of zonular instability and should alert the surgeon to the
possibility of intraocular complications (Küchle et al. 2000).
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In the Finnish Register of the Visually Handicapped (Stakes & Näkövammaisten
Keskusliitto 2000), the prevalence of glaucoma-related visual impairment is 11.4%
of all visual impairment among persons 65 years of age and older, ranging from
10% at 70 years to 15% among those 80-90 years of age. Similarly, Hirvelä &
Laatikainen (1995) found a 12.3% prevalence of glaucoma among the visually
handicapped population 70 years of age or older. In the total population of the
latter study, 1.5% suffered from glaucomatous visual impairment.
2.1.3 Prevalence of cataract
According to the World Health Organization (1982), cataract is the most frequent
agent of visual impairment worldwide. A total of 16-20 million people in the
developing countries suffer from blindness due to cataract (Yorston 1998), which
represents 42% of all cases of blindness worldwide (Thylefors et al. 1995).
In Finland, cataract was considered to be the main cause or an important cause of
low vision or blindness in 3.4% of the population 70 years of age or older and a
concurrent cause of visual impairment in 75.4% of elderly persons suffering from
low vision or blindness (Hirvelä et al. 1995). More than 35 000 cataract operations
are performed in Finland every year, and the number is steadily rising. The
cataract surgery rate is higher for females compared with males (Lundström et al.
1999).
2.1.4 Cataract surgery methods
During the 1980s and early 1990s, the preferred technique in cataract surgery was
extracapsular cataract extraction (ECCE) with posterior chamber intraocular lens
(PC-IOL) implantation. The first 2 original articles of this thesis (I-II) reflect this
period. Currently, most cataract operations are performed with phacoemulsification
(PHACO) techniques (Krootila 1999). The last 3 articles (III-V) refer to this
technique.
With the development of cataract surgery methods from ECCE to PHACO, the rate
of complications has decreased. Using the ECCE technique, the risk for
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complications was especially high in EG eyes (Raitta & Setälä 1986, Lumme &
Laatikainen 1993). The risk for vitreous loss in EXF eyes was found to be 7.4-9%
(Naumann et al. 1988, Lumme & Laatikainen 1993) compared with less than 2% in
non-EXF eyes (1.7% (Lumme & Laatikainen 1993), 1.8% (Naumann et al. 1988)). In
a series by Wirbelauer et al. (1998), no vitreous loss occurred after PHACO in
pure cataract eyes with or without EXF. Scorolli et al. (1998) found a risk of 1% for
vitreous loss in non-EXF eyes compared with 7.1% for EXF eyes after PHACO
surgery. Viscoelastics are used in both methods to reduce tissue trauma and
endothelial cell loss, and to serve as a space maintainer, especially during capsular
bag IOL implantation.
2.1.5 Early IOP rise after cataract surgery
In nonglaucomatous eyes, IOP rise in the early (1-7 days) postoperative period is a
well-known phenomenon both after intracapsular cataract extraction (ICCE; Kirsch
1964, Kaufman & Stahl 1965, Lantz & Quigley 1973) and after ECCE PC-IOL
(Gross et al. 1988, Calissendorf & Hamberg-Nyström 1993, Lagrèze et al. 1996).
Early postoperative increase in IOP in nonglaucomatous cataract eyes has also
recently been reported after PHACO and IOL (Lagrèze et al. 1996, Hopkins et al.
1998).
Before publication of Article I of this thesis, several reports of an IOP rise 1 or 2
days after ECCE IOL in OAG eyes had been reported (McGuigan et al. 1986, Vu &
Shields 1988, Krupin et al. 1989, Ruusuvaara et al. 1990). The highest IOP
increase was usually seen 2-24 hours postoperatively (Barron et al. 1985, Olivus &
Thornburn 1985, Passo et al. 1985, Alpar et al. 1988, Lane et al. 1991). Although
the elevated IOP usually resolves within 24-72 hours (Olivius & Thornburn 1985,
Næser et al. 1986), this elevation increases the potential risk for retinal artery
occlusion and ischaemic optic neuropathy (Hayreh 1980) and may be particularly
harmful in patients with pre-existing glaucomatous nerve damage.
The most important reason for early IOP rise after cataract surgery is incomplete
removal of viscoelastics (Næser et al. 1986). Viscoelastic substances may block
the aqueous outflow (Berson et al. 1983, Passo et al. 1985, Næser et al. 1986).
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Pressure elevation may be avoided without the use of viscoelastic substances
(Schipper et al. 2000). Postoperative pressure rise may also be prevented or
controlled by postoperative topical medication. Immediately after cataract surgery,
dorzolamide or latanoprost instilled dropwise was found to be effective in reducing
IOP increase 6 hours postoperatively, but after 20-24 hours only dorzolamide was
effective (Rainer et al. 1999). However, neither dorzolamide nor latanoprost
prevented occasional IOP spikes of 30 mmHg or higher 6 hours postoperatively
(Rainer et al. 1999). Lai et al. (2000) showed that a single dose of timolol gel
instilled immediately after operation produced a significant postoperative IOP
decrease in as little as 2 hours and up to 24 hours after PHACO surgery.
Acetazolamide given 1 hour preoperatively has also been found to decrease IOP
on the 1st postoperative day (Byrd & Singh 1998).
2.1.6 Long-term IOP after cataract surgery
2.1.6.1 Pure cataract eyes
Beyond the immediate postoperative period, persistent IOP decrease after ECCE
PC-IOL in normal eyes was reported, but after 2 years the IOP returned to baseline
(Cinotti et al. 1988). After PHACO IOL, IOP decrease lasting for 3-12 months has
recently also been documented (Suzuki et al. 1994, Tennen & Masket 1996, Cekic
et al. 1998, Tong & Miller 1998, Wirbelauer et al. 1998). In only a few reports was
the follow-up time longer: Jahn (1997) reported IOP decrease 5 years
postoperatively and Suzuki et al. (1997) 10 years postoperatively. Significant IOP
decrease has also been found in nonglaucomatous EXF eyes 3-6 months after
surgery with PHACO IOL (Dosso et al. 1997, Wirbelauer et al. 1998).
2.1.6.2 Open-angle glaucoma eyes
Laatikainen (1971) showed a 16% IOP decrease in eyes with OAG after ICCE. In
the series of Handa et al. (1987), IOP improved and the need for postoperative
medication decreased after ECCE PC-IOL after a follow-up of 1-2 years. The
positive effect of ECCE IOL surgery on IOP and/or medication of glaucomatous
eyes has also been reported by other investigators (Savage et al. 1985, McGuigan
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et al. 1986, McMahan et al. 1986, Hansen et al. 1987). PHACO IOL has also
maintained IOP control in medically controlled glaucomatous eyes (Peräsalo 1997),
but the possible presence of early IOP spikes must be considered (Jürgens et al.
1997).
2.2 ARGON LASER TRABECULOPLASTY
In 1979, Wise & Witter published the 1st case series of argon laser therapy for
treatment of OAG with demonstrable long-term reduction in IOP. The argon laser
emits either blue-green (wavelength 488-514 nm) or green (514 nm) light. It shows
excellent optical transmission through the cornea and the intraocular media and is
selectively absorbed by biologic chromophores (mainly melanin and haemoglobin).
Fluorophotometric studies by Wise & Witter (1979) proposed that heat-induced
shrinkage of the trabecular meshwork (TM) would cause its circumferential
contraction and opening of trabecular spaces. This would result in an increase in
the facility of aqueous outflow through the layers of the TM and into Schlemm’s
canal (Wise & Witter 1979, Yablonski et al. 1985). However, similar effectiveness
of 180° versus 360° treatment suggests a more complex mechanism for the action
of ALT (Schwartz et al. 1983). Clearly, the ALT mechanism is still incompletely
understood. However, evidence is mounting that a biological mechanism may be
responsible for a major portion of ALT’s therapeutic effects (Park et al. 2000).
Reports on ALT show that it reduces IOP by 7-10 mmHg with or without medication
in phakic eyes with primary POAG at up to a 4-10-year follow-up (Wise 1981,
Thomas et al. 1982, Schwartz et al. 1983, Rouhiainen et al. 1988, Ticho & Nesher
1989, Shingleton et al. 1993). The overall success rate varies between 32% and
55% at 10 years (Ticho & Nesher 1989, Shigleton et al. 1993). The 9-year follow-
up results of the Glaucoma Laser Trial (GLT) Research Group (1995) suggested
that laser treatment for newly diagnosed POAG is at least as effective as
medication treatment. There was no difference in the number of eyes that
progressed to filtering surgery, but there was a 38% reduction in the total number of
medication days in the laser group compared with the medication group (Glaucoma
Laser Trial Research Group 1995). ALT is especially indicated in EG in which it is
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successful in 53% of the patients (with medication in most of the eyes) at 2 years
and in 34% at 4 years (Hetherington 1988). ALT is even recommended for primary
therapy in EG (Thomas et al. 1984, Tuulonen 1984, Bergeå et al. 1999). It was
suggested that eyes with coexisting cataract and glaucoma may benefit from ALT
before cataract surgery (Brown et al. 1985, Savage et al. 1985).
2.3 POSTOPERATIVE POSTERIOR CAPSULAR OPACIFICATION
A significant problem occurring after cataract surgery is PCO (Percival & Setty
1988, Corboy & Novak 1989, Maltzman et al. 1989, Born & Ryan 1990, Apple et al.
1992). PCO can result in significant impact on vision, including marked decrease in
VA, impaired contrast sensitivity and glare disability (Sunderraj et al. 1992,
Claesson et al. 1994). This warrants various measures to prevent development of
PCO. PCO may be treated with Nd:YAG laser capsulotomy, and almost 90% of the
patients achieved improved VA after capsulotomy (Keates et al. 1984, Skolnick et
al. 2000).The overall risk for complications occurring after capsulotomy was found
to be 10.5% (Skolnick et al. 2000).
2.3.1 Prevalence of PCO
The incidence of preoperative posterior capsular plaque in eyes undergoing
cataract surgery has been found to be 10% (Vasavada et al. 1997). After cataract
surgery, PCO has been reported in 10-50% of eyes 3-5 years after ECCE IOL and
PHACO IOL (McDonnel et al. 1983, Sterling & Wood 1986, Moisseiev et al. 1989,
Apple et al. 1992, Kappelhof & Vrensen 1992, Sundelin & Sjöstrand 1999). In a
recent meta-analysis by Schaumberg et al. (1998) the estimated rate for PCO was
11.8% at 1 year, 20.7% at 3 years and 28.4% at 5 years after ECCE, and there
was no evidence of significant decline in the incidence. Wilhelmus & Emery (1980)
reported a mean opacification time of 26 months after surgery and Dangel et al.
(1994) a mean opacification time of 27.6 months.
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2.3.2 Mechanism of PCO
PCO results from proliferation of pre-equatorial lens epithelial cells (LECs) and
their migration from the capsular periphery to the central area to produce Elschnig’s
pearls or from fibroblastic transformation causing capsular fibrosis (McDonnell et al.
1983-1985). Iron-transport protein, a transferrin synthesized and secreted by LECs,
may facilitate proliferation of LECs (Davidson et al. 1998).
2.3.3 Relationship of PCO to other diseases and factors
Glaucoma has been reported to be associated with higher PCO incidence (Gunning
& Greve 1991). Patients with a history of uveitis are also presumed to have higher
risk for PCO, but little information is available to support this. Dana et al. (1997)
found no difference between eyes with and without uveitis; however, the risk for
higher incidence of PCO in uveitis eyes could not be ruled out in their study. In
diabetes mellitus both higher (Ionides et al. 1994) and lower rates (Zaczek &
Zetterström 1999) of PCO have been found than in persons without diabetes. A
higher frequency of PCO has also been found in eyes with EXF (Zetterström 1993,
Küchle et al. 1997, Scorolli et al. 1998).
2.3.4 Reduction of PCO
2.3.4.1 Peroperative methods
To avoid PCO formation gentle manipulation during surgery is recommended. Iris
irritation has been found to cause higher PCO incidence (Gunning & Greve 1991),
but in a series by Ninn-Pedersen et al. (1997) glaucomatous eyes with
sphincterotomy were found to have a 30% lower risk for subsequent need for
Nd:YAG laser treatment than eyes that did not undergo sphincterotomies. With the
continuous curvilinear capsulorhexis (CCC) technique, the risk for PCO may be
diminished (Apple et al. 1992, Ravalico et al. 1996, Birinci et al. 1999). A large
capsulorhexis with a diameter greater than that of the IOL optic diameter allows
fusion of the anterior capsule flap to the posterior capsule, setting up a mechanical
barrier to LEC migration from the equator and leading to less PCO (Kappelhof et
al. 1986, Tetz et al. 1988). Hollick et al. (1999a) found that more PCO occurs when
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the anterior capsulotomy edge comes into contact with the posterior capsule. When
the capsulorhexis opening is smaller than the IOL optic diameter, the anterior
capsule leaf is mechanically separated from the posterior capsule and therefore
might lead to an increase in LEC ingrowth (Hiles & Johnson 1980, Yamada et al.
1995). However, Ravalico et al. (1996) found that PCO was less frequent in the
group in which the anterior capsule was in contact with the lens optic for the entire
360°.
PCO increases with cortical remnants (Nishi 1989). Use of hydrodissection (Peng
et al. 2000a), mechanical removal of capsular cells and cytotoxic drugs may reduce
PCO (McDonnell et al. 1988, Apple et al. 1992). Hydrodissection was first
documented by Faust in 1984, and a more detailed clinical description was
published by Fine in 1992. Hydrodissection is the best available means to help
remove equatorial LECs and thus alleviate the incidence of PCO (Peng et al.
2000a). The incidence for PCO is lower in eyes implanted with PC-IOL than in
nonimplanted eyes (Nishi 1986).
2.3.4.2 IOL design and material
Before collecting material for the present article (V) in 1995, the literature on IOL
design and material was scanty, but in recent years several reports have been
published on these subjects. Recent works suggest that lens implant design rather
than lens material may be the most important factor in the prevention of PCO
(Apple et al. 1992, Nishi & Nishi 1999). This has been illustrated by various rates of
PCO between silicone lenses of a plate or loop haptic design (Cumming 1993,
Mamalis et al. 1996b). Low capsulotomy rates for posterior convex lenses (Downing
1986) and for biconvex lenses compared with planoconvex IOLs (Martin et al.
1992) have been found. Planoconvex optics inhibited migration of LECs better than
biconvex optics (Nagamoto & Eguchi 1997). Posterior convexity of the IOL optics is
thought to reduce LEC migration onto the posterior capsule by mechanically
producing apposition of the posterior lens surface to the capsule (Frezzotti &
Caporossi 1990). Sharp-edged biconvex or planoconvex IOLs had lower rates of
PCO than those with round edges (Nagata & Watanabe 1996, Hollick et al. 1999b,
Küçüksümer et al. 2000). Analysis of PC-IOLs obtained postmortem showed that a
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square, truncated optic edge appeared to provide the maximum impediment to cell
growth behind the IOL optic (Peng et al. 2000b).
IOLs made from polyacrylic appear to be associated with a significantly reduced
degree of PCO and lower capsulotomy rates when compared with poly(methyl
methacrylate) (PMMA) and silicone lenses 2 years postoperatively (Ursell et al.
1998). Oshika et al. (1996) found an 11.1% capsulotomy rate in eyes with acrylic
lenses 2 years after surgery. Hayashi et al. (1998) reported a 30.4% rate in a
PMMA IOL group, which is significantly greater than the 5.7% and 2.7% rates in the
silicone and acrylic groups, respectively, 2 years postoperatively. The capsulotomy
rate for the silicone group was 24% after 3 years, compared with 33% for the
PMMA group (Olson & Crandall 1998). Kobayashi et al. (2000) reported a 7.1%
capsulotomy rate for polyacrylic lenses compared with 38.1% for PMMA lenses 3
years postoperatively.
26
3. AIMS OF THE STUDY
The principal aims of the present study were:
- To examine the effect of ECCE with IOL implantation on IOP in OAG eyes.
- To examine the effect of preoperatively performed ALT on postoperative IOP after
ECCE with IOL implantation in OAG eyes.
- To examine the effect of PHACO with PC-IOL implantation on IOP in OAG eyes.
- To examine the effect of PHACO with PC-IOL implantation on IOP in pure cataract
eyes.
The subsidiary aims were:
- To compare preoperative VA, surgical complications and visual outcome of
glaucomatous eyes after ECCE surgery with glaucomatous and nonglaucomatous
eyes after PHACO surgery.
- To evaluate PCO formation in relation to 2 different IOL materials after PHACO
and IOL implantation.
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4. PATIENTS AND METHODS
4.1 DEFINITIONS
4.1.1 Open-angle glaucoma
Glaucoma diagnosis was confirmed by private practitioners. The diagnostic criteria
commonly used for OAG were the presence an IOP > 22 mmHg with optic disc
changes and/or glaucomatous field defects and an open chamber angle. No
additional examinations concerning glaucoma diagnosis (visual field examination,
IOP diurnal curve, photographs of optic nerve head) were performed before
surgery. At the time of cataract surgery, IOP was controlled (IOP < 21 mmHg with or
without medication) in most eyes. IOP level was defined with single IOP
measurement. If the eye had EXF on the lens surface or pupillary margin, the
glaucoma was defined as EG. The presence of EXF was determined after dilatation
of the pupil.
The terms used to define OAG were simple glaucoma (SG) and capsular glaucoma
(CG; I, II). The currently more commonly used terms POAG and EG were used in
other studies (III, IV, V).
4.1.2 Cataract
All patients had been diagnosed with cataract and referred for cataract surgery by
private practitioners; the type of cataract was not specified.
4.1.3 Central PCO
Postoperative PCO was classified into 4 grades: Grade 1 - clear capsule, Grade 2 -
mild central opacification with VA loss of 0 - 1 lines and Grade 3 - serious PCO
with decrease in vision by 2 lines or more between controls at 4 months and 2
years due to evident opacification of the centre of the posterior capsule as seen in
the slit lamp, with the patient complaining of visual impairment (glare, reduced
vision or both) from opacification. Eyes in which capsulotomy had already been
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performed were classified as Grade 4. Grades 3 and 4 together were defined as
having clinically significant PCO. VAs were compared with the 4-month control.
4.1.4 Visual acuity
The best-corrected visual acuity (BCVA) was determined at 5 m using Snellen
acuity cards. BCVA was categorized into 3 groups: > 0.4, 0.05-0.3 and counting
fingers or less (< 0.05; I, II).
In the last 3 articles BCVA was categorized according to the classification of the
WHO (1973) as > 0.3, 0.25-0.1, and < 0.1 (III-V).
In the final analysis of this study, BCVA was categorized into 4 groups: > 0.8, 0.4-
0.7, 0.05-0.3 and < 0.05 to make comparison between the groups possible (I, III-V).
4.2 SELECTION OF THE PATIENTS
4.2.1 Inclusion and exclusion criteria
I
A consecutive series of 103 eyes with OAG (both POAG and EG), having ECCE
IOL implantation at the Glaucoma Unit of the Helsinki University Eye Hospital
during 1987-1988 and followed up for at least 1 year were included. The eyes had
undergone no previous ocular surgery, but eyes with previous ALT were included.
A total of 35 patients (34%) were lost to follow-up. These patients were excluded
from the analysis in this thesis. Thus, the final study group consisted of 64 OAG
eyes.
II
From the 103 eyes collected for I, 26 consecutive age- ( + 2 years) and diagnosis-
matched pairs which differed with respect to ALT treatment were selected for this
investigation.
III
A total of 42 consecutive OAG eyes operated on for cataract by the same surgeon
1-3.7 years previously were included. Four eyes with previous ocular surgery (3
with trabeculectomy and 1 with krypton laser cyclophotocoagulation) were
excluded.
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IV
A series of 196 consecutive eyes operated on for cataract by the same surgeon in
1995 were collected. From this series we excluded eyes with prior intraocular
diseases that could possibly affect IOP, such as glaucoma (10 eyes), diabetic
retinopathy (7 eyes), previous contusion injury (5 eyes), previous retinal
detachment (5 eyes), keratoconus (2 eyes), retinitis pigmentosa (2 eyes), uveitis (2
eyes), choroidal tumour (1 eye), retinal dystrophy (1 eye) and previous venous
thrombosis of the retina (1 eye). Thus, the final series consisted of 160 pure
cataract eyes. The eyes had a history of normal IOP, except 1 non-EXF eye which
had ocular hypertension but normal visual fields. The other patients were
normotensive.
V
Within the previous series of 196 eyes, 80 consecutive cataract eyes were
prospectively randomized into 2 groups, using an envelope method: 40 eyes
receiving a silicone and 40 eyes receiving an acrylic IOL. In this study eyes with
previous ocular diseases or ocular surgery were not excluded.
4.2.2 Patients
I
A consecutive series of 103 eyes from 99 patients (77 female, 22 male) with
controlled OAG (POAG or EG) were enrolled. Thus, 4 patients had both eyes
included, but this small number of bilateral cases was not thought to affect the
results. Thirty-seven (36%) of these eyes had POAG and 66 (64%) had EG. The
mean age of the POAG patients was 75.9 + 7.3 (55-88) years and of the EG
patients 78.1 + 6.7 (59-91) years (Table 1). A total of 35 patients (34%) were lost
to follow-up. These patients were excluded from analysis in this thesis. Thus, the
final study group consisted of 64 eyes (51 female, 13 male) that were followed up
for 1-3.6 (mean 2.1) years. Twenty-six of these eyes had POAG (41%) and 38
(59%) had EG. The mean age of the POAG patients was 75.7 + 8.1 (55-88) years
and of the EG patients 77.7 + 7.1 (59-90) years.
Table 1. Patients in articles I - V
ARTICLE I II III IV V
PATIENTS
Total number 103 52 38 160 80
POAG
mean age + SD (range)
EG
mean age + SD (range)
37
75.9 + 7.3 (55-88)
66
78.1 + 6.7 (59-91)
17
76.8 + 7.8 (59.3-84.6)
21
79.5 + 5.7 (67.1-89.3)
Non-ALT-treated
mean age + SD (range)
ALT-treated
mean age + SD (range)
17 EG + 9 POAG
76.2 + 6.9 (59-87)
17 EG + 9 POAG
76.2 + 6.9 (59-87)
Nonglaucomatous EXF
mean age + SD (range)
Nonglaucomatous
mean age + SD (range)
23
76.3 + 11.2 (43.3-89.7)
137
66.7 + 13.8 (20.5-88.8)
Silicone IOL group
mean age + SD (range)
40
67.2 + 13.9 (37.1 -87.1)
Acrylic IOL group
mean age + SD (range)
40
67.1 + 14.1(28.0 - 85.7)
POAG = primary open-angle glaucoma, EG = exfoliation glaucoma, ALT = argon laser trabeculoplasty, EXF = exfoliation, IOL = intraocular lens,
SD = standard deviation
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II
From the 103 eyes collected for I, 26 age- ( + 2 years) and diagnosis-matched
pairs that differed with respect to preoperative ALT were selected for special
investigation (39 female, 13 male). Both the laser-treated and nonlaser-treated
group consisted of 9 POAG and 17 EG patients. The mean age of the patients was
76.2 + 6.9 years in both groups (59-87 years). ALT had been performed in eyes
with uncontrolled glaucoma on maximal tolerated medication 1.4 + 1.3 years before
cataract surgery. Follow-up data after 0.5-3 (mean 2.1) years were available in all
cases (Table 1).
III
A series of 38 consecutive OAG eyes without previous ocular surgery were
operated on for cataract using PHACO and PC-IOL implantation during 1995-1996.
The study group consisted of 17 eyes with POAG and 21 eyes with EG (23 female,
15 male); 8 of the eyes had had previous ALT. The mean age of the POAG
patients was 76.8 + 7.8 (59.3-84.6) years and for EG patients 79.5 + 5.7 (67.1-
89.3) years. One eye in the POAG group and 4 eyes in the EG group had age-
related macular degeneration (ARM) and 1 eye with EG had diabetic retinopathy.
The initial data were collected from the files and all patients were invited for re-
examination 1-3.7 (mean 2.8) years after cataract surgery. A total of 9 eyes (24%)
were lost to follow-up for several unidentified reasons (Table 1).
IV
According to the inclusion criteria, 160 pure cataract eyes were selected for this
study. The mean age of the 76 men and 84 women was 68.1 + 13.9 (range 20.5-
89.7) years (137 nonglaucomatous eyes, whose mean age was 66.7 + 13.8 (20.5-
88.8) years; 23 nonglaucomatous EXF eyes, whose mean age was 76.3 + 11.2
(43.3-89.7) years). Of these, 136 (85%) were available for follow-up study. A total
of 24 patients (15%) were lost to follow-up at 1-2.7 (mean 2.2) years for several
reasons: 11 patients had died, 5 were in poor health and 2 patients expressed
disinterest. Of the remaining 6 patients who did not respond to follow-up invitation,
5 were over 85 years of age and 1 was 52 years of age (Table 1).
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V
Eighty consecutive eyes (41 female, 39 male) operated on for cataract in 1995 were
prospectively randomized using an envelope method in 2 groups, one receiving a
silicone IOL (Si-30NB, Allergan Medical Optics, Los Angeles, CA, USA) with
polypropylene haptics and the other an acrylic IOL (AcrySof MA60BM, Alcon
Laboratories, Fort Worth, TX, USA) with PMMA haptics. The mean age in the
silicone group was 67.2 + 13.9 (range 37.1-87.1) years and in the acrylic group
67.1 + 14.1 (range 28.0-85.7) years. In the silicone group 21/40 (52.5%) of the
patients were men and 19/40 (47.5%) were women and in the acrylic group 18/40
(45%) were men and 22/40 (55%) were women. A total of 22 eyes (55%) in the
silicone group and 16 eyes (40%) in the acrylic group had pure cataract; the
remaining eyes had various concurrent ocular diseases. A total of 7 eyes (9%) were
lost to late follow-up at 1-2.4 (mean 2.1) years for various unidentified reasons
(Table 1).
4.3 METHODS USED IN THE STUDY
4.3.1 Study design
The 1st studies (I, II) involved retrospective interventional case series. The
preoperative data collected from the files of the Helsinki University Eye Hospital
included BCVA, biomicroscopy findings and single IOP measurement using
Goldmann applanation tonometry, as well as information on possible glaucoma
medications recorded in case records. Due to difficulties caused by the opaque
lens, visual field examination was not performed routinely. Follow-up data were
collected from the early postoperative period (1-14 days), at 2-6 weeks and at 0.5-
3.6 (mean 2.1) years postoperatively. An IOP rise > 30 mmHg was recorded during
the early postoperative period (mean 1.6 days, range 1-5 days). Postoperative data
for 0.5-3.6 years were collected either from the hospital files or with the aid of
private practitioners.
The later studies (III-V) were also retrospective interventional case series, except
V, which was a prospective randomized trial comparing 2 types of IOLs.
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Preoperative data including BCVA, biomicroscopy findings and IOP records (single
measurement of IOP) as well as information on the glaucoma type, other possible
eye diseases, previous medication, and laser and surgical treatment were
collected. Due to difficulties caused by the opaque lens, visual field examination
was not performed routinely. Preoperative and follow-up data concerning the 1st
postoperative day and 1-week and 4-month controls were collected from the files
of the Helsinki University Eye Hospital. On the 1st postoperative day, the topical
and oral medications used were recorded. For long-term follow-up, the patients
were invited to a re-evaluation study in the clinic after 1-3.7 (mean 2.8) years (III),
1-2.7 (mean 2.2) years (IV) and 1-2.4 (mean 2.1) years (V), or the data were
collected with the aid of private practitioners. Both uncorrected VA and BCVA were
measured at 5 m. Biomicroscopy and IOP measurement were performed one time
only with Goldmann applanation tonometry. The pupil was dilated if needed with
tropicamide drops (TropicamidR), and the fundus was examined with a Volk 90-
dioptre (D) lens.
4.3.2 Techniques of cataract surgery
4.3.2.1 Extracapsular cataract extraction technique
Cataract surgery was performed with ECCE, which included a fornix-based
conjunctival flap, an 11-mm 2-step corneoscleral incision and injection of
viscoelastics (I, II). In most of the eyes 1% sodium hyaluronate (HealonR) was used.
A 360° can opener, or an envelope capsulotomy was performed before nuclear
expression. The cortex was aspirated with a Cavitron Kelman or Mentor infusion-
aspiration (IA) unit. Peripheral iridectomy with radial iridotomy was performed as
needed. One or several sphincterotomies for pupillary dilatation were required in
one-fourth of the eyes and iris-suturing was performed when needed. A PMMA IOL
with prolene or polypropylene loops was implanted either in the bag or sulcus. Four
EG patients did not receive an IOL, and 1 planned ICCE was performed. Wounds
were closed with interrupted 10-0 nylon monofilament sutures. Viscoelastic
substance was aspirated either with the IA device or expressed by injection of
acetylcholine (MiocholR) at the end of the operation.
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4.3.2.2 Phacoemulsification technique
All surgeries were performed using PHACO and were outpatient operations (III-V).
The operations were performed either under topical or paraocular anaesthesia in
all except 1 patient, who needed general anaesthesia. Patients in the topical
group received 4 drops of bupivacaine hydrochloride 0.75% (MarcaineR) 4 times.
Patients in the paraocular group received 2 paraocular injections of a solution of
lidocaine 2%, bupivacaine 0.75% and hyaluronidase (WydaseR) 3.75 IU/ml. The
volume of the block was 6-8 ml depending on the weight of the patient.
All eyes underwent the standard PHACO IOL operation (Fine et al. 1993)
performed by the same surgeon (RJU). Short-term mydriatics, 1% cyclopentolate
and 2.5% phenylephrine, as well as scopolamine were used for pupillary dilatation.
Surgery was performed using a 4-mm scleral tunnel or corneal incision with no
sutures. Capsulorhexis was performed under viscoelastic protection (a combination
of chondroitin sulphate and hyaluronic acid (ViscoatR)), followed by hydrodissection
and PHACO of the nucleus. The cortex was removed with an IA device.
Sphincterotomies were performed if needed. An IOL was implanted in the bag in all
cases. The viscoelastic substance was carefully removed at the end of the
operation, and either a collagen shield soaked with antibiotics and cortisone was
patched on the eye or a parabulbar antibiotic and cortisone injection given.
4.4 ARGON LASER TRABECULOPLASTY
ALT for the patients included here was performed either at the Helsinki University
Eye Hospital or by private practitioners in different places. Details of the technique
were not always recorded.
The most commonly used technique during the late 1980s included use of a spot
size of 50 µm and pulse duration of 0.1 s. The power was initially at 400-500 mW
and was adjusted to produce a slight blanching of the anterior TM. The argon laser
burns were placed between the nonpigmented anterior third and the pigmented
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posterior two-thirds of the TM. Approximately 35-50 spots were placed evenly along
180° of the angle. Most physicans chose to treat only 180° of the angle.
4.5 STATISTICAL METHODS
The postoperative values were compared with preoperative values in all 5 studies.
I
The paired t-test and Wilcoxon signed rank test were used to analyse IOP change
over time. The Mann-Whitney rank sum test, t-test and chi-square test were used to
compare POAG and EG eyes.
II
The paired t-test was used to compare IOP over time and Fisher’s exact test to
compare glaucoma medications.
III
The paired t-test and Wilcoxon signed rank test were used to analyse IOP and
medication over time.
IV
All data were analysed with the SAS software package (release 6.12, SAS Institute
Incorporation, Cary, NC, USA). Normality was tested with Shapiro-Wilk statistics.
The Wilcoxon 2-sample test and t-test were used to compare EXF and non-EXF
eyes as well as the 2 groups of different IOLs. The Wilcoxon signed rank test and
paired t-test were used to analyse IOP change over time. Spearman correlation
coefficients were calculated to analyse the association between IOP and age, axial
length or PHACO time.
V
The chi-square and 2-tailed Fisher’s exact tests were used for statistical analyses.
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5. RESULTS
5.1 COMPLICATIONS OF EXTRACAPSULAR AND PHACOEMULSIFICATION
CATARACT SURGERY IN OPEN-ANGLE GLAUCOMA AND
NONGLAUCOMATOUS EYES (I, III-V)
5.1.1 Early complications in extracapsular surgery (I)
The posterior capsule ruptured without vitreous loss in 3 EG eyes (8%), but in none
of the POAG eyes. PC-IOL could still be implanted in 2/3 eyes. Vitreous loss
occurred in 3 EG eyes (8%), but in none of the POAG eyes. There were no cases
of massive haemorrhage. Fibrinous effusion essentially was equally common in
both groups: 8% of the POAG (2 eyes) and 5% of the EG eyes (2 eyes). There
were no cases of flat or shallow anterior chamber (Table 2).
5.1.2 Early complications in phacoemulsification surgery (III-V)
In the POAG group 1 posterior capsule rupture occurred, and in 1 EG eye the
zonules were loose but the IOL could be implanted in the bag in all cases (III). In
the nonglaucomatous eyes zonules were broken nasally in 1 non-EXF eye, but the
bag remained intact and an IOL was implanted in the bag. None of the eyes
showed extensive postoperative inflammation, and no additional medications were
needed in non-EXF or EXF eyes (IV). Intraoperative complications in the silicone
and acrylic groups were few; there was 1 posterior capsule tear in the silicone
group and tearing of the anterior capsule in 2 eyes from the acrylic group (V; Table
2).
5.1.3 Posterior capsular opacification in relation to silicone and acrylic IOLs
(V)
At the 4-month control examination, no clinically significant PCO was found in any
of the eyes, but mild central capsular opacification with VA loss of 0-1 lines was
noted in 8 eyes (20%) of the silicone IOL group and in 9 eyes (23%) of the acrylic
IOL group. At the 2-year control, 22 eyes (61%) in the silicone group and 28 eyes
Table 2. Early complications (I, III-V)
COMPLICATIONS ECCE IOL in OAG*
(I)
PHACO IOL in OAG (III) PHACO IOL in
nonglaucomatous eyes (IV)
PHACO and silicone or acrylic
IOL implantation (V)
POAG
26 eyes (%)
EG
38 eyes (%)
POAG
17 eyes (%)
EG
21 eyes (%)
EXF
23 eyes (%)
non-EXF
137 eyes (%)
Silicone IOL
40 eyes (%)
Acrylic IOL
40 eyes (%)
Anterior capsular tear - - - - - - - 2 (5)
Posterior capsular
tear
- 3 (8)** 1 (6) - - - 1 (3) -
Loose / broken
zonules
- - - 1 (5) - 1 (<1) - -
Vitreous loss, no lens - 3 (8) - - - - - -
Iris prolapse 1 (4) - - - - - - -
AC haemorrhage - 1 (3) - - - - - -
Fibrinous effusion 2 (8) 2 (5) - - - - - -
Optic disc infarction - 1 (3) - - - - - -
ECCE IOL = extracapsular cataract extraction and intraocular lens implantation, OAG = open-angle glaucoma, PHACO IOL = phacoemulsification and
intraocular lens implantation, POAG = primary open-angle glaucoma, EG = exfoliation glaucoma, EXF = exfoliation, AC = anterior chamber
* including 1 eye with planned intracapsular surgery, ** 1 aphakia, 2 with IOL
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(76%) in the acrylic group showed clear posterior capsules (P = 0.18). Mild central
opacification with VA decrease of 0-1 lines was observed in 5 eyes (14%) in the
silicone group and 2 eyes (5%) in the acrylic group, while serious PCO was found
in 8 eyes (22%) and 4 eyes (11%), respectively. Capsulotomy had already been
performed in 1 eye (3%) in the silicone group and in 3 eyes (8%) in the acrylic
group. Thus, a total of 9 eyes (25%) in the silicone group and 7 eyes (19%) in the
acrylic group had developed clinically significant PCO (P = 0.53; Table 3). Change
in VA in the rows is seen in Table 4.
Table 3. Posterior capsular opacification in 40 eyes with silicone and 40 eyes with acrylic
IOL 1-2.4 years after phacoemulsification surgery
Posterior capsule Silicone IOL Acrylic IOL
n = 40 (%*) n = 40 (%*)
Clear capsule 22 61 28 76
Mild central opacification 5 14 2 5
Serious PCO 8 22 4 11
Capsulotomy rate 1 3 3 8
Unknown 4 - 3
IOL = intraocular lens
PCO = posterior capsular opacification
*Percentage of known cases
Table 4. Posterior capsular opacification and visual acuity loss 1-2.4 years after PHACO IOL in 40 silicone and 40 acrylic IOL eyes
SILICONE IOL ACRYLIC IOL
Clear capsule Central PCO Clear capsule Central PCO
Decrease in VA Mild Serious Mild Serious
No decrease 16 5 - 17 - -
1 row 6 - - 7 2 -
2 rows - - 3 3 - 2
3 rows - - 3 1 - -
4 rows - - 2 - - -
5 rows - - - - - 1
6 rows - - - - - 1
Capsulotomy rate 1 3
Unknown 4 3
Total 40 40
PHACO IOL = phacoemulsification and intraocular lens implantation, IOL = intraocular lens, PCO = posterior capsular opacification, VA = visual acuity
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Throughout the entire study group, there was no significant difference in the
formation of clinically significant PCO in eyes with or without concurrent ocular
diseases (in 29% in those with other diseases and in 14% in those without; P =
0.13). Of the eyes with pure cataract, 2/20 (10%) in the silicone group and 3/15
(20%) in the acrylic group showed significant PCO (P = 0.631), while of the eyes
with other diseases 7/16 (44%) in the silicone group and 4/22 (18%) in the acrylic
group showed significant PCO (P = 0.147). Thus, in eyes with silicone IOLs
significant PCO was more commonly found if there was concurrent ocular disease
(44% vs. 10%; P = 0.049), while in acrylic IOL eyes concurrent ocular disease did
not contribute to the formation of significant PCO (20% vs. 18%; P = 1.0). The
prevalence of clear capsules in eyes without other diseases was 85% (17/20) in
the silicone group and 73% (11/15) in the acrylic group (P = 0.43). The
corresponding figures in eyes with other diseases were 31% (5/16) in the silicone
group and 77% (17/22) in the acrylic group (P = 0.005).
A total of 6 eyes in both groups had either EG or EXF syndrome without glaucoma.
In the silicone group, capsulotomy had already been performed in 1 eye, 2 showed
mild central PCO without VA decrease and 1 showed clinically significant PCO. In
the acrylic group all 6 eyes showed clear capsules. All 4 eyes with POAG were in
the acrylic group; 1 of these showed clinically significant PCO and capsulotomy
had been performed in another. A total of 3 eyes with silicone IOLs had glaucoma,
1 of which showed clinically significant PCO and 2 mild central PCO. In the acrylic
group 7 eyes had glaucoma, and 2 showed capsulotomy already performed or
clinically significant PCO. A total of 5 patients had diabetic maculopathy (4 in the
silicone group and 1 in the acrylic group), 2 of the silicone IOL eyes showed clear
capsules and the remaining 3 eyes were lost to late control.
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5.2 PREOPERATIVE VISUAL ACUITY AND VISUAL OUTCOME AFTER
SURGERY
5.2.1 Extracapsular surgery in glaucomatous eyes (I)
Preoperatively, 3 POAG eyes (12%) and none of the EG eyes showed VA > 0.4, 18
POAG eyes (69%) and 17 EG eyes (45%) a VA of 0.05-0.3, and 5 POAG eyes
(19%) and 21 EG eyes (55%) a VA of < 0.05. From 1 to 3.6 years postoperatively,
the VA was 0.8 or better in 7 POAG eyes (27%) and in 14 EG eyes (37%). Nine
POAG eyes (35%) and 7 EG eyes (18%) showed VA of 0.4-0.7. A total of 8 POAG
eyes (31%) and 13 EG eyes (34%) showed VA of 0.05-0.3 and 2 POAG eyes (7%)
and 4 EG eyes (11%) remained at the finger-counting level. The reasons for the
poor VA level in POAG were glaucoma (1 eye) and combined glaucoma and ARM
(1 eye). In EG eyes the low vision was a consequence of glaucoma (1 eye),
postoperative IOP rise (48 mmHg) and ischaemic optic neuropathy (1 eye), central
venous thrombosis (unrelated to cataract surgery) and haemorrhagic glaucoma (1
eye), while in 1 eye the reason was unknown (Table 5).
5.2.2 Phacoemulsification surgery in glaucomatous eyes (III)
Preoperatively, 4 POAG eyes (23%) and 2 EG eyes (9%) showed VA > 0.4, 10
POAG eyes (59%) and 15 EG eyes (72%) a VA of 0.05-0.3, and 3 POAG eyes
(18%) and 4 EG eyes (19%) a VA of < 0.05. After a follow-up of 1-3.7 years, 4
POAG eyes (33.5%) and 7 EG eyes (41%) had VA of 0.8 or better and 4 POAG
eyes (33.5%) and 10 EG eyes (59%) showed VA 0.4-0.7. A total of 3 (25%) POAG
eyes showed VA of 0.05-0.3 and 1 POAG eye a VA of < 0.05 (due to ARM; Table
6).
5.2.3 Phacoemulsification surgery in nonglaucomatous eyes (IV)
Preoperatively 5 EXF eyes (22%) and 30 non-EXF eyes (22%) showed a VA > 0.4,
while 9 EXF eyes (39%) and 79 non-EXF eyes (58%) showed VA of 0.05-0.3, and
9 EXF eyes (39%) and 27 non-EXF eyes (20%) a VA of < 0.05. From 1 to 2.7 years
postoperatively, 6 EXF eyes (32%) and 69 non-EXF eyes (59%) showed VA of 0.8
or better; and 9 EXF eyes (47%) and 36 non-EXF eyes (31%) had VA of 0.4-0.7. A
Table 5. Visual acuity preoperatively and 1-3.6 years after ECCE IOL in OAG eyes
PREOPERATIVE AFTER 1-3.6 YEARS
EYES (%*) EYES (%*)
VISUAL ACUITY POAG EG TOTAL POAG EG TOTAL
> 0.8 0 0 0 7 (27) 14 (37) 21 (33)
0.4-0.7 3 (12) 0 3 (5) 9 (35) 7 (18) 16 (25)
0.05-0.3 18 (69) 17 (45) 35 (55) 8 (31) 13 (34) 21 (33)
< 0.05 5 (19) 21 (55) 26 (40) 2 (7)** 4 (11)*** 6 (9)
TOTAL 26 38 64 26 38 64
ECCE IOL = extracapsular cataract extraction and intraocular lens implantation
OAG = open-angle glaucoma
POAG = primary open-angle glaucoma
EG = exfoliation glaucoma
*Percentage of known cases
**due to glaucoma (1 eye), glaucoma and age-related macular degeneration (1 eye)
*** due to glaucoma (1 eye), postoperative IOP rise and ischemic optic neuropathy (1 eye), central venous thrombosis and haemorrhagic glaucoma (1 eye),
unknown (1 eye)
Table 6. Visual acuity preoperatively and 1-3.7 years after PHACO IOL in OAG eyes
PREOPERATIVE AFTER 1-3.7 YEARS
EYES (%*) EYES (%*)
VISUAL ACUITY POAG EG TOTAL POAG EG TOTAL
> 0.8 0 0 0 4 (33.5) 7 (41) 11 (39)
0.4-0.7 4 (23) 2 (9) 6 (16) 4 (33.5) 10 (59) 14 (48)
0.05-0.3 10 (59) 15 (72) 25 (66) 3 (25) - 3 (10)
< 0.05 3 (18) 4 (19) 7 (18) 1 (8)** - 1 (3)**
TOTAL 17 21 38 12 17 29
UNKNOWN - - - 5 4 9
PHACO IOL = phacoemulsification and intraocular lens implantation
OAG = open-angle glaucoma
POAG = primary open-angle glaucoma
EG = exfoliation glaucoma
* Percentage of known cases
** Due to age-related macular degeneration
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total of 4 EXF eyes (21%) and 9 non-EXF eyes (8%) showed a VA of 0.05-0.3, and
3 non-EXF eyes (2%) but none of the EXF eyes a VA of < 0.05. All the 3 non-EXF
eyes with poor VA had ARM; 1 had additional PCO (Table 7).
5.2.4 Phacoemulsification surgery and silicone or acrylic IOL implantation (V)
Preoperatively, 15% of silicone IOL eyes and 27% of acrylic IOL eyes showed VA
of 0.4 or better, 70% of eyes in the silicone IOL group and 48% in the acrylic IOL
group showed VAs of 0.05-0.3 and 15% and 25%, respectively, showed VAs of <
0.05. Four months postoperatively, the visual outcome was quite similar in both
groups. At the latest examination 1-2.4 years postoperatively, 16 silicone IOL eyes
(44%) and 18 acrylic IOL eyes (49%) had VA of 0.8 or better. Thirteen silicone IOL
eyes (36%) and 16 acrylic IOL eyes (43%) had VA of 0.4-0.7. A total of 14% of the
silicone IOL eyes and 8% of the acrylic IOL eyes showed VA of 0.05-0.3. In the
silicone IOL group 2 eyes (6%) showed VA of < 0.05 due to ARM; in the acrylic IOL
group no such eyes were found (Table 8).
5.3 EFFECT OF CATARACT SURGERY ON INTRAOCULAR PRESSURE
5.3.1 Early postoperative pressure rise (I, III, IV)
On the 1st postoperative day(s), IOP was significantly higher than the preoperative
level both in OAG and pure cataract eyes in all 3 study groups. After ECCE IOL (I)
IOP rose by 42.6% from a preoperative level of 19.5 + 5.5 mmHg to 26.4 + 12.6
mmHg (P = 0.013) in POAG eyes and by 38.5% from a preoperative level of 19.3 +
3.7 mmHg to 25.5 + 9.9 mmHg (P = 0.001) in EG eyes. The difference in
preoperative IOPs and IOPs on the 1st postoperative day between POAG and EG
eyes was not significant (P = 0.907 and 0.762, respectively; Table 9). IOP rose to
30 mmHg or more in about 30% of the eyes with no significant difference between
POAG (10 POAG eyes, 38%) and EG (10 EG eyes, 26%; P = 0.45). The highest
IOP was 60 mmHg in POAG and 50 mmHg in EG eyes.
After PHACO IOL (III) IOP rose by 68.1% from a preoperative level of 17.9 + 4.2
mmHg to 29.1 + 11.8 mmHg on the 1st postoperative day (P = 0.0011) in POAG
Table 7. Visual acuity preoperatively and 1-2.7 years after PHACO IOL in nonglaucomatous EXF and non-EXF eyes
PREOPERATIVE AFTER 1-2.7 YEARS
EYES (%*) EYES (%*)
VISUAL ACUITY EXF non-EXF TOTAL EXF non-EXF TOTAL
> 0.8 0 2 (1) 2 (1) 6 (32) 69 (59) 74 (55)
0.4-0.7 5 (22) 28 (21) 33 (21) 9 (47) 36 (31) 45 (33)
0.05-0.3 9 (39) 79 (58) 88 (55) 4 (21) 9 (8) 13 (10)
< 0.05 9 (39) 27 (20) 36 (23) - 3 (2)** 3 (2)**
TOTAL 23 136 159 19 117 136
UNKNOWN - 1 1 4 20 24
PHACO IOL = phacoemusification and intraocular lens implantation
EXF = exfoliation
*Percentage of known cases
** All 3 had age-related macular degeneration; 1 had additional posterior capsular opacification
Table 8. Visual acuity preoperatively and 1-2.4 years after PHACO IOL in eyes with silicone or acrylic IOLs
VISUAL
ACUITY
PREOPERATIVE
EYES (%)
AFTER 4 MONTHS
EYES (%)
AFTER 1-2.4 YEARS
EYES (%*)
Silicone IOL Acrylic IOL Silicone IOL Acrylic IOL Silicone IOL Acrylic IOL
> 0.8 0 2 (5) 21 (53) 26 (65) 16 (44) 18 (49)
0.4-0.7 6 (15) 9 (22) 13 (33) 9 (23) 13 (36) 16 (43)
0.05-0.3 28 (70) 19 (48) 5 (12) 5 (12) 5 (14) 3 (8)
< 0.05 6 (15) 10 (25) 1 (2) 0 2 (6) 0
TOTAL 40 40 40 40 36 37
UNKNOWN - - - - 4 3
IOL = intraocular lens, VA = visual acuity, *Percentage of known cases
Table 9. Mean IOP and medication preoperatively and 1-3.6 years after ECCE IOL in OAG eyes
POAG EG
Number
of eyes
Number of
medications
(Mean*)
IOP (mmHg)
(Mean + SD)
Change
(%**)
(Mean + SD)
P-value** Number
of eyes
Number of
medications
(Mean*)
IOP (mmHg)
(Mean + SD)
Change
(%**)
(Mean + SD)
P- value**
Preoperative 26 1.7 19.5 + 5.5 38 1.5 19.3 + 3.7
Postoperative
1-5 days 26 - 26.4 + 12.6 + 42.6 + 73.4 0.013 38 - 25.5 + 9.9 + 38.5 + 60.9 0.001
2-6 weeks 20 1.0 18.6 + 7.4 - 0.01 + 40.0 0.595 35 0.7 19.1 + 5.5 +1.9 + 34.1 0.548
1-3.6 years 26 1.2 17.3 + 2.9 - 5.8 + 27.4 0.043 38 1.1 17.5 + 5.7 - 6.6 + 30.0 0.003
IOP = intraocular pressure, ECCE IOL = extracapsular cataract extraction and intraocular lens implantation, OAG = open-angle glaucoma,
POAG = primary open-angle glaucoma, EG = exfoliation glaucoma, SD = standard deviation,
* Including eyes with no medication, ** Compared with preoperative level
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eyes and correspondingly by 48.5% from 18.6 + 2.4 mmHg to 27.5 + 13.3 mmHg (P
= 0.009) in EG eyes. Preoperatively, IOP was higher in EG than in POAG eyes (P
= 0.0235), but on the 1st postoperative day no difference in IOPs was found (P =
0.6213; Table 10). IOP rose to 30 mmHg or more in 7 POAG eyes (41.2%), and in
8 EG eyes (38.1%). The difference between the groups was not significant in this
respect (P = 0.847). The highest IOP was 62 mmHg in POAG eyes and 60 mmHg
in EG eyes. The pressure rise was not related to the type of cataract incision, since
41.7% of the eyes with clear corneal incision and 35.7% of the eyes with scleral
incision showed an IOP of 30 mmHg or more on the 1st postoperative day (P =
0.717).
In nonglaucomatous eyes (IV), the early pressure rise was 28.4% from 16.3 + 2.7
mmHg to 21.0 + 8.5 mmHg (P = 0.0061) in EXF eyes and 29.9% from 16.2 + 3.4
mmHg to 20.5 + 5.7 mmHg (P = 0.001) in non-EXF eyes after PHACO IOL. The
difference between EXF and non-EXF eyes was not significant (P = 0.622; Table
11). On the 1st postoperative day, IOP rose to 30 mmHg or more in 4 EXF eyes
(17.4%) and in 8 non-EXF eyes (5.8%). The difference between the groups was not
significant (P = 0.073). The highest IOP was 48 mmHg in EXF eyes and 45 mmHg
in non-EXF eyes.
During the early postoperative period the IOP returned to the preoperative level.
From 2 to 6 weeks after ECCE IOL the mean IOP was 18.6 + 7.4 mmHg in POAG
eyes ( - 0.01% compared with the preoperative level; P = 0.595) and 19.1 + 5.5
mmHg in EG eyes ( + 1.9%; P = 0.548; I). The difference between the groups was
not significant (P = 0.31; Table 9). One week after PHACO IOL, IOP was 18.2 + 4.7
mmHg in POAG eyes ( + 6.8%; P = 0.8354) and 17.0 + 4.8 mmHg in EG eyes ( -
8.5%; P = 0.1265), while at 4 months postsurgery, IOP remained at the
preoperative level of 17.4 + 3.3 mmHg in POAG eyes ( + 1.5%; P = 0.6340). In EG
eyes IOP further decreased to 15.0 + 3.9 mmHg ( - 19.2%; P = 0.0003; III). The
difference between the groups at 1 week and 4 months was not significant (P =
0.9635 and 0.6364, respectively; Table 10).
Table 10. Mean IOP and medication preoperatively and 1-3.7 years after PHACO IOL in OAG eyes
IOP = intraocular pressure, PHACO IOL = phacoemulsification and intraocular lens implantation, OAG = open-angle glaucoma
POAG = primary open-angle glaucoma, EG = exfoliation glaucoma, SD = standard deviation
* Including eyes with no medication, ** Compared with preoperative level
POAG EG
Number
of eyes
Number of
medications
(Mean*)
IOP (mmHg)
(Mean + SD)
Change
(%**)
(Mean + SD)
P-value** Number
of eyes
Number of
medications
(Mean*)
IOP (mmHg)
(Mean + SD)
Change
(%**)
(Mean + SD)
P-value**
Preoperative 17 1.7 17.9 + 4.2 21 1.7 18.6 + 2.4
Postoperative
1 day 17 - 29.1 + 11.8 + 68.1 + 75.4 0.0011 21 - 27.5 + 13.3 + 48.5 + 74.9 0.009
1 week 17 0.8 18.2 + 4.7 + 6.8 + 43.5 0.8354 21 0.8 17.0 + 4.8 - 8.5 + 25.5 0.1265
4 months 16 1.1 17.4 + 3.3 + 1.5 + 28.8 0.6340 21 1.1 15.0 + 3.9 - 19.2 + 21.5 0.0003
1-3.7 years 12 1.2 16.0 + 2.2 - 13.4 + 5.8 0.0001 17 1.5 14.5 + 3.3 - 20.8 + 16.5 0.0011
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In nonglaucomatous EXF eyes, IOP decreased 1 week after PHACO IOL by 12%
from a preoperative level of 16.3 + 2.7 mmHg to 14.2 + 3.0 mmHg (P = 0.001) and
in non-EXF eyes by 5.9% from a preoperative level of 16.2 + 3.4 mmHg to 15.0 +
2.9 mmHg (P = 0.001; IV). After 4 months a significant decrease continued to 12.8
+ 2.7 mmHg ( -20.2%) in the EXF eyes (P = 0.0002) and to 13.8 + 2.7 mmHg ( -
13.2%) in non-EXF eyes (P = 0.001). The difference between the non-EXF and
EXF groups at 1 week (P = 0.2511) and 4 months (P = 0.932) was not significant
(Table 11).
5.3.2 Long-term IOP (I, III, IV)
After ECCE IOL the long-term effects were measured for 1-3.6 years
postoperatively. The mean IOP in POAG was 5.8% lower than the preoperative
value (P = 0.043), and in EG eyes the decrease was 6.6% (P = 0.003). The
difference between the IOPs (17.3 + 2.9 mmHg and 17.5 + 5.7 mmHg,
respectively) was not significant (P = 0.627; Table 9). IOP reduction > 4 mmHg
compared with the preoperative level was seen in over 30% of the eyes (8/26
POAG and 12/38 EG eyes; I ).
After PHACO IOL the last examination was performed 1-3.7 years postoperatively.
IOP decreased by 13.4% in POAG eyes (P = 0.0001) and by 20.8% in EG eyes (P
= 0.0011). The difference between the IOPs in POAG and EG eyes (16.0 + 2.2
mmHg and 14.5 + 3.3 mmHg, respectively) was not significant (P = 0.1765; Table
10). IOP reduction > 4 mmHg was seen in 38.5% of the eyes (1/10 POAG and 9/16
EG eyes; III). Patient age (P = 0.1852), axial length (P = 0.08943), and IOL type (P
= 0.06769) did not influence IOP change.
In pure cataract eyes the last IOP level 1-2.7 years after surgery in EXF eyes was
23.2% lower than the preoperative level (P = 0.0001) and in non-EXF eyes the
decrease was 21.2% (P = 0.001). The difference between IOPs in EXF eyes (12.3 +
2.6 mmHg) and non-EXF eyes (12.7 + 2.7 mmHg) was not significant (P = 0.5837;
IV; Table 11).
Table 11. Mean IOP preoperatively and 1-2.7 years after PHACO IOL in nonglaucomatous EXF and non-EXF eyes
EXF non-EXF
Number of
eyes
IOP (mmHg)
(Mean + SD)
Change (%*)
(Mean + SD)
P-value* Number of
eyes
IOP (mmHg)
(Mean + SD)
Change (%*)
(Mean + SD)
P-value*
Preoperative 23 16.3 + 2.7 137 16.2 + 3.4
Postoperative
1 day 23 21.0 + 8.5 + 28.4 + 42.3 0.0061 137 20.5 + 5.7 + 29.9 + 42.9 0.001
1 week 23 14.2 + 3.0 - 12.0 + 16.6 0.001 136 15.0 + 2.9 - 5.9 + 19.3 0.001
4 months 21 12.8 + 2.7 - 20.2 + 19.3 0.0002 132 13.8 + 2.7 -13.2 + 19.1 0.001
1-2.7 years 19 12.3 + 2.6 - 23.2 + 12.7 0.0001 117 12.7 + 2.7 - 21.2 + 15.9 0.001
IOP = intraocular pressure, PHACO IOL = phacoemulsification and intraocular lens implantation, EXF = exfoliation, non-EXF = nonexfoliation, SD = standard
deviation, * Compared with preoperative level
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5.4 EFFECT OF CATARACT SURGERY ON GLAUCOMA MEDICATION
5.4.1 Extracapsular extraction group (I)
In the ECCE group, the preoperative glaucoma medication in POAG eyes
comprised a mean of 1.7 drugs. Three (8%) EG eyes managed without medication,
while the rest had a mean of 1.6 drugs. At the latest examination 1-3.6 years after
cataract surgery, 5 POAG eyes (19%) had no medication and the rest had a mean
of 1.4 drugs. Fourteen EG eyes (37%) managed without medication; the rest had a
mean of 1.7 drugs. After surgery medication was increased in 3 POAG (12%) and
4 EG eyes (11%).
5.4.2 Phacoemulsification groups (III, IV)
In the PHACO group, POAG and EG eyes had a mean of 1.7 drugs preoperatively.
At the last examination 1-3.7 years postoperatively, 83.3% of the POAG eyes and
88.2% of the EG eyes had a mean of 1.4 and 1.7 drugs, respectively, while 16.7%
of POAG and 11.8% of EG eyes had no medication (2/12 POAG and 2/17 EG
eyes). A total of 41.6% of POAG and 29.4% of EG eyes had less medication than
preoperatively (5/12 POAG and 5/17 EG eyes), and over 50% had as many drugs
as preoperatively (6/12 POAG and 10/17 EG eyes). Medication had to be
increased in 8.3% of the POAG and in 11.8% of the EG eyes (1/12 POAG and 2/17
EG eyes; III). After a follow-up of 1-2.7 years, glaucoma medication with 1 topical
drug was initiated in 1 initially nonglaucomatous non-EXF eye (IV).
5.5 EFFECT OF PREOPERATIVE ARGON LASER TRABECULOPLASTY ON
POSTOPERATIVE INTRAOCULAR PRESSURE AND GLAUCOMA MEDICATION
AFTER EXTRACAPSULAR CATARACT EXTRACTION (II)
5.5.1 Intraocular pressure
In the ALT group, the mean prelaser IOP was 25.4 + 6.6 mmHg and the
preoperative IOP level before cataract surgery with or without medication was 18.9
+ 3.1 mmHg. From 0.5 to 3 years after cataract surgery, the mean IOP had
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decreased further to 16.9 + 3.2 mmHg (P = 0.026), and 8 eyes (31%) showed a
decrease in IOP of 4 mmHg or more compared with the preoperative level.
In the nonlaser group, the preoperative IOP with or without medication was 19.1 +
3.7 mmHg. From 0.5 to 3 years after cataract surgery, the mean IOP was 17.5 +
2.5 mmHg (P = 0.086). Six of these eyes (23%) showed a decrease in IOP of 4
mmHg or more compared with the preoperative level.
5.5.2 Glaucoma medication
Preoperatively, 4 ALT-treated eyes (15%) had no glaucoma medication and the
remaining 22 (85%) had an average of 1.7 drugs. One patient in the nonlaser
group did not use medication preoperatively; the remaining eyes had an average of
1.2 drugs.
From 0.5 to 3 years after cataract surgery, 10 ALT-treated eyes (39%) managed
without glaucoma medication, and the remaining 16 eyes (61%) had an average of
1.6 drugs. Eight nonlaser eyes (31%) had no medication and the remaining 18
eyes (69%) had an average of 1.5 drugs. Medication had been increased in 2/26
(7.7%) of ALT-treated eyes and in 4/26 (15.4%) of non-ALT-treated eyes.
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6. DISCUSSION
6.1 SUBJECTS AND METHODS
6.1.1 Cataract surgery and pre- and postoperative visual acuity in
glaucomatous and nonglaucomatous eyes
The material was collected during 1987-1988 (I, II) and 1995-1996 (III-V). During
this almost 10-year period, the favoured cataract operative technique has
progressed from ECCE to PHACO surgery. Due to improved technique, the
incidence of complications has decreased, especially in EXF eyes, and
consequently the indications for cataract surgery have changed. In the present
study this is seen e.g. as better preoperative vision in the later PHACO series (III)
compared with the earlier ECCE series (I). In both series, eyes having undergone
previous glaucoma surgery were excluded.
In glaucoma eyes the preoperative VA before ECCE (I) was considerably poorer
than in the later series before PHACO (III). In these 2 substudies the lower level for
favourable vision was different (0.4 in the ECCE group, 0.3 in the PHACO group),
but otherwise the definitions were similar. To compare these studies more easily we
used criteria employed in the ECCE group (I). Preoperatively, only 5% of the eyes
in the ECCE series had `good vision´ (0.4 or better), while in the PHACO series
16% showed VA of 0.4 or better. Correspondingly, in the ECCE series 95% of the
eyes showed VA of 0.3 or worse, and almost half (40% of all eyes) were blind (VA
< 0.05; WHO definition). In the PHACO series a total of 84% showed VA of 0.3 or
worse, and 18% of all eyes were blind. In the nonglaucomatous eyes the
preoperative VA before PHACO surgery was similar to that in the glaucoma eyes.
This indicates that with the development of cataract surgical technique, the visual
indications for surgery have changed, and cataract surgery in glaucomatous eyes is
performed at an earlier stage.
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The visual results after surgery have also changed from the ECCE to the PHACO
period. After ECCE, the long-term VA was 0.8 or better in 33% of the eyes and 0.4-
0.7 in 25% of the eyes, while in the PHACO series 39% of the glaucoma eyes
attained a VA of 0.8 or better and 48% a VA of 0.4-0.7. Glaucoma patients in the
ECCE series were patients in the Glaucoma Unit of the Helsinki University Eye
Hospital and therefore many may have had more advanced glaucoma than patients
in the later PHACO series. This is also supported by the finding that in the ECCE
series glaucoma was the leading cause of blindness, while in the PHACO series
none of the patients were blind due to glaucoma.
The late postoperative visual outcome in glaucomatous eyes after PHACO and IOL
implantation was similar to that in nonglaucomatous eyes, and in both groups the
results corresponded with those in other studies (Uusitalo & Tarkkanen 1998,
Kobayashi et al. 2000, Lundström et al. 2000). This indicates that the visual
outcome in glaucomatous eyes after modern cataract surgery is comparable to that
in healthy eyes. In the present PHACO series in nonglaucomatous and
glaucomatous patients, the overall complication rate was low in all groups, with no
remarkable difference between EXF and non-EXF eyes. These results are also
comparable to the findings of Menkhaus et al. (2000), who found no difference in
complication rate between EXF and non-EXF eyes in a series containing both
nonglaucomatous and glaucomatous patients.
6.2 EFFECT OF EXTRACAPSULAR AND PHACOEMULSIFICATION CATARACT
SURGERY ON INTRAOCULAR PRESSURE IN OPEN-ANGLE GLAUCOMA AND
NON-GLAUCOMATOUS EYES (I, III, IV)
6.2.1 Early IOP rise after cataract surgery
During the early postoperative period, the IOP exceeded the preoperative level
both after ECCE and PHACO in glaucomatous and nonglaucomatous eyes. IOP
values of 30 mmHg or higher were slightly more frequent after PHACO than after
ECCE; in POAG the prevalences were 41% vs. 38% and in EG 38% vs. 26%,
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respectively. In nonglaucomatous eyes, high pressure values were less frequent:
17% in EXF eyes and 6% in non-EXF eyes.
An early postoperative IOP increase after cataract surgery may be caused by
several factors, including the use of viscoelastic substances (Glasser et al. 1986,
Næser et al. 1986), watertight wound closure (Jaffe 1990, Bömer et al. 1995),
inflammation, hyphaema (Kooner et al. 1988), increased vascular permeability with
increased protein concentration in the aqueous, inflammation and blockage of the
TM by lenticular debris or viscoelastic substance (Berson et al. 1983, Passo et al.
1985, Næser et al. 1986, Gross et al. 1988, Mastropasqua et al. 1998). The
properties of different viscoelastics may vary with regard to the removal process
and the time required to aspirate the viscoelastics from the anterior chamber (Assia
et al. 1992, Arshinoff 1998, Rainer et al. 2000). The remaining viscoelastic
substance exits the eye via outflow channels without being metabolized (Lai et al.
2000). One factor that may affect outflow facility is the chain length of the
viscoelastics used. Most authors suggest that long chains may have greater
difficulty traversing the TM and juxtacanalicular tissue (Equi et al. 1997). According
to Lane et al. (2000) chain length is a less important determinant of outflow facility
changes than ease of removal by IA. Thus, incomplete removal of the viscoelastic
substance is a major cause of postoperative IOP increase, especially in small-
incision cataract surgery. Therefore, it is important to aspirate the viscoelastic
substance from both the anterior chamber and the capsular bag behind the
implanted IOL (Wedrich et al. 1992, Kohnen et al. 1996). Surgical techniques for
removing viscoelastic substances, especially from behind the IOL, have been
described (Wedrich et al. 1992, Kohnen et al. 1996), but complete prevention of
postoperative pressure increase has not been achieved with any technique.
Different viscoelastics used in our ECCE and PHACO series may contribute to
different IOPs on the 1st postoperative day. In the PHACO series the viscoelastic
used was a combination of chondroitin sulphate and hyaluronic acid, which was
found to induce higher IOPs on the 1st postoperative day compared with hyaluronic
acid alone (Schwenn et al. 2000). The mean irrigation volume after ECCE was also
found to be double the volume used in PHACO (Ohrloff & Zubcov 1997), which
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may partially explain our findings of lower IOP in the ECCE series on the 1st
postoperative day.
The surgical technique itself may also affect postoperative IOP. In the present
study, the early pressure rise in glaucomatous eyes was greater and more frequent
after PHACO than after ECCE, but this effect may have been due to differences in
the use of viscoelastic material rather than the technique (PHACO vs. ECCE) itself.
Byrd & Singh (1998) found no difference in pressure elevation between
nonglaucomatous eyes undergoing ECCE and those undergoing PHACO. In
glaucomatous eyes, patients with combined cataract surgery had fewer early IOP
elevations compared with eyes undergoing pure cataract surgery (Storr-Paulsen et
al. 1998). In a study on POAG eyes by Kim et al. (1999a) and in a study by
Shingleton et al. (1999) on glaucoma eyes operated on using clear-corneal incision
and PHACO, early IOP rise was insignificant. Böhmer et al. (1995) also found
small-incision sutureless PHACO to be associated with a significantly lower
postoperative early IOP rise than in the group with sutures in nonglaucomatous
eyes.
The presence of EXF may increase the risk of postoperative pressure rise. In eyes
with EXF, a high frequency of postoperative inflammatory response after ECCE
surgery has been found (Drolsum et al. 1993, 1994). In the present study after
PHACO, neither extensive postoperative inflammation nor increased risk of early
IOP rise was seen in EG eyes. In the group of nonglaucomatous eyes, the early
pressure rise was slightly more frequent in EXF than in non-EXF eyes (17% vs.
6%), but the finding was not statistically significant. A low frequency of inflammatory
response after PHACO was also found by Drolsum et al. (1998).
After the early postoperative pressure rise the IOP soon decreased to the
preoperative level or below, both after ECCE (I) and after PHACO (III). After
ECCE the preoperative pressure level was attained 2-4 weeks postoperatively, and
after PHACO the preoperative level was already recorded 1 week postoperatively.
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6.2.2 Long-term IOP after cataract surgery
Long-term pressure reduction was significant, both after ECCE and PHACO and in
POAG and EG. After ECCE, the mean decrease in POAG and EG eyes was similar
(6% for POAG and 7% for EG). This was, however, less than reported by Arici et al.
(2000), who found a decrease of 17% for EG eyes 1.5 years after ECCE IOL. In the
present PHACO series, the results correspond with those of Arici et al. (2000). In
POAG eyes the reduction was 13%, in EG eyes 21%. After ECCE the IOP had
decreased by 4 mmHg or more in 31% of eyes with POAG and in 34% of eyes with
EG. After PHACO, the corresponding percentages were 10% for POAG and 56%
for EG eyes. At the latest examination 54% vs. 34% of the eyes had no or less
medication than preoperatively, and in only 12% vs. 10% was the medication
increased after ECCE or PHACO surgery, respectively. This is also comparable to
the results found by Arici et al. (2000). According to criteria of Bigger & Becker
(1971), the eyes were classified as `improved´ if there was a greater than 3-mmHg
decrease in IOP with the same medication or a decrease in medication with the
same IOP ( + 3 mmHg). Eyes were classified as `unchanged´ if the mean
postoperative IOP and medications were the same, and `worse´ if there was an
increase in mean IOP greater than 3 mmHg with the same medication or an
increase in medication to achieve the same IOP ( + 3 mmHg). According to these
criteria, long-term control after PHACO IOL in OAG eyes was improved in 69%
(20/29) of the eyes, unchanged in 17% (5/29) of the eyes and worse in 14% (4/29)
of the eyes.
Peräsalo (1997) compared eyes with POAG and EG and found no difference in the
mean preoperative pressure. At 1 year 34% of the patients needed no glaucoma
medication, 26% used less medication and 37% were on the same medication as
preoperatively. The corresponding figures in our study 1-3.7 years after PHACO
were 10%, 35% and 55%, respectively. Kim et al. (1999a) found that in 90% of
POAG eyes, IOP control improved and in 10% it was unchanged 16 months after
PHACO .
We did not evaluate the effect of ECCE on the IOP level in nonglaucomatous eyes,
but after PHACO similar and statistically significant IOP reduction was noted both in
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EXF (23%) and non-EXF eyes (21%). The long-term IOP-reducing effect after
PHACO in nonglaucomatous eyes was comparable to that in EG eyes (21%) and
more pronounced than in POAG (13%). A number of other studies have also
demonstrated that ECCE and IOL implantation lowers IOP to some extent in both
glaucomatous (McMahan et al. 1986, Handa et al. 1987, Steuhl et al. 1992) and
nonglaucomatous eyes, but in most of these studies the follow-up time has been
relatively short.
Shingleton et al. (1999) found a decrease in IOP in eyes with glaucoma 6 months
after PHACO IOL, but after 1 year IOP had returned to baseline. Hayashi et al.
(2000) found a decrease in IOP 1 year after PHACO IOL, but the IOP-reducing
effect may not be long-lasting in eyes with OAG, because the aqueous outflow
system is basically compromised. Kim et al. (1999a) found significant decrease in
IOP 16.4 months after PHACO IOL.
After PHACO IOL, IOP decrease in nonglaucomatous eyes lasting for 3-12 months
has recently been documented (Suzuki et al. 1994, Tennen & Masket 1996, Cekic
et al. 1998, Tong & Miller 1998, Wirbelauer et al. 1998, Shingleton et al. 1999,
Hayashi et al. 2000). Only a few reports with longer follow-up are available; Jahn
(1997) reported IOP decrease up to 5 years (mean, however, 17 months) and
Suzuki et al. (1997) reported IOP decrease 10 years postoperatively. Suzuki et al.
(1997) reported significant decrease of IOP in eyes in which the preoperative IOP
was 25 mmHg or higher, while in eyes with low (< 10 mmHg) IOP, the IOP
significantly increased with time.
From the results of the present study, the mechanism of the IOP-reducing effect of
cataract surgery cannot be resolved. Steuhl et al. (1992) and Hayashi et al. (2000)
attributed the IOP-reducing effect of cataract surgery to widening of the anterior
chamber angle, which may well affect the inflow and outflow facility of the aqueous
humour (Meyer et al. 1997, Kee & Moon 2000). In our study no correlation between
IOP change and axial length was found. Contraction of the ciliary muscle resulting
from various stimulations leads to increase in outflow facility (Van Busirk 1973,
1976, Kaufman & Bárány 1976). Reduction in zonular tension after cataract
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extraction may affect ciliary muscle mobility, and outflow facility may increase more
or less than before cataract surgery (Kee & Moon 2000). The angle-widening and
chamber-deepening seen after cataract surgery appeared to improve aqueous
outflow facility to some degree in both glaucomatous eyes (Steuhl et al. 1992) and
in pure cataract eyes (Cekic et al. 1998), although this effect may have been
transient (Seah et al. 1997). In OAG and nonglaucomatous eyes the anterior
chamber configuration was, however, almost the same after surgery as before
(Hayashi et al. 2000). The rinsing effect of IA may be compared with that of
trabecular aspiration, in which the mechanism by which IOP levels are lowered is
the relief of outflow resistance (Jacobi et al. 2000). Cataract removal may also be
associated with biochemical or blood-aqueous barrier alterations that could
influence the IOP levels (Handa et al. 1987, Althaus et al. 1994). In addition,
postoperative alterations in aqueous humour dynamics related to enhanced
aqueous humour outflow (Epstein et al. 1978) through either the TM or via
uveoscleral routes as well as a possible reduction in aqueous humour production
may reduce the pressure (Hart 1992).
Management of coexisting glaucoma and cataract has been debated for years. The
following options are currently the options of choice: 1) cataract surgery first
followed by glaucoma surgery, if needed, 2) glaucoma surgery first followed by
cataract surgery, or 3) combined cataract-glaucoma surgery.
Several considerations must be accounted for in determining whether to combine
cataract surgery with glaucoma surgery. The patient’s ability to comply with the
medical regimen is variable, and factors that influence compliance include daily
dose frequency, forgetfulness, inconvenience and unaffordability. According to
Patel & Spaeth (1995), 59% of the patients failed to take their medications
precisely as prescribed. Giraldi et al. (1999) found an overall compliance rate of 86-
95% in different age-groups. Combined trabeculectomy and PHACO decreases
IOP effectively, and visual recovery is also marked (Mamalis et al. 1996a, Peräsalo
et al. 1997). ECCE IOL combined with trabeculectomy was beneficial in the long-
term control of IOP and prevention of visual field loss compared with pure ECCE
IOL (Bobrow 2000). According to Anders et al. (1997) the decrease in IOP in
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glaucoma patients is greater after combined than pure cataract operation. In
contrast, no difference in IOP decrease, medication or VA results was found
between combined or pure PHACO cataract surgery by Yalvac et al. (1997).
Combined procedures may, however, possess an increased risk for postoperative
complications (Wedrich et al. 1995, Peräsalo et al. 1997, Jacobi et al. 1999).
Our results suggest that cataract surgery alone, or possibly in combination with
glaucoma medication, is sufficient to decrease IOP in most OAG eyes readily
controlled medically or with prior ALT, assuming that the eyes do not have profound
optic nerve damage and visual field loss. However, in the present study we had no
information on visual fields and/or glaucoma progression. In general, we may
reserve the combined procedures for eyes that are at risk for further optic nerve
damage as a consequence of early postoperative pressure elevation, those with
significant optic nerve damage and visual field loss in which greater long-term
pressure reduction is required, those who have had failed filtration surgery and
those who are noncompliant with medical therapy (Storr-Paulsen 1995, Obstbaum
1999, Bobrow 2000). In cases of profound optic nerve damage, possible early IOP
spikes must be considered (Tennen & Masket 1996, Jürgens et al. 1997, Peräsalo
et al. 1997).
6.3 EFFECT OF PREOPERATIVE ARGON LASER TRABECULOPLASTY ON
POSTOPERATIVE INTRAOCULAR PRESSURE AND GLAUCOMA MEDICATION
AFTER CATARACT SURGERY (II)
Reports on ALT show that it reduces IOP by 7-10 mmHg with or without medication
in phakic eyes with POAG at up to 4-10 years of follow-up (Wise 1981, Thomas et
al. 1982, Schwartz et al. 1983, Rouhiainen et al. 1988, Ticho & Nesher 1989,
Shingleton et al. 1993). The overall success rate varies between 32% and 55% at
10 years (Ticho & Nesher 1989, Shingleton et al. 1993, respectively). ALT was
performed 16.9 + 15.4 months before cataract surgery to improve pressure control
in poorly controlled eyes, and theoretically the IOP-lowering effect of ALT could
have maintained IOP at a stable level during the study. In the present study, both
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POAG and EG eyes were included in the ALT-treated and nonlaser-treated group,
and there was no significant difference in preoperative IOPs between the groups,
but the selection of eyes for ALT had not been at random. Thus, the study group
with preoperative ALT probably had more advanced glaucoma with poorer
prognosis than eyes previously controlled with medical therapy. After cataract
surgery, however, long-term IOP control was better in the ALT-treated than in the
nontreated group. This indicates that the successful effect of ALT on IOP was not
eliminated by cataract surgery.
6.4 POSTERIOR CAPSULAR OPACIFICATION (V)
The incidence of PCO formation varies greatly between various reports. The lack of
a standardized definition of PCO, differences in examination methodology and/or in
surgical techniques and the IOL styles used in different studies may have
contributed to the variability occurring among studies (Schaumberg et al. 1998).
The PCO criteria are often based on subjective methods such as VA, contrast
sensitivity or the Nd:YAG laser capsulotomy rate. We regarded a VA decrease of 2
lines or more in the presence of central PCO or wrinkling to be significant (Oshika
et al. 1996, Küchle et al. 1997). In some recent studies a decrease of 3 lines or
more has been used (Kim et al. 1999b).
Among the variables affecting PCO are patient characteristics such as age and
type of cataract, surgical variables such as capsulotomy type and size, IOL style
and placement (capsular bag vs. ciliary sulcus) and the surgical technique (PHACO
vs. ECCE, hydrodissection). Careful removal of LECs and cortical remnants
reduces PCO and other complications attributable to retained or regenerated
epithelial cells. Hydrodissection facilitates removal of lens fibres and epithelial cells
(Apple et al. 1992, 2000), but it may be performed insufficiently if the surgeon is
hesitant about fluid-pressure-induced distension or rupture of the posterior capsule
(Hurvitz 1991, Kershner 1992, Ota et al. 1996, Yeoh 1996). The in-the-bag mode of
IOL fixation decreases the incidence of PCO (Apple et al. 1985, 1992, Hansen et al.
1988, Vilhjalmsson & Lucas 1992, Apple & Rabb 1998), because it enhances the
barrier effect of the IOL optic. Careful, gentle manipulation of the eye at all stages
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of surgery minimizes intraoperative and postoperative breakdown of the blood-
aqueous barrier and inflammation, decreasing the stimuli for cellular response and
PCO (Miyake et al. 1984). In the present study, all surgical operations were
performed by the same experienced surgeon using the same technique, and all
IOLs were implanted in the capsular bag. This probably minimized variations in the
surgical technique and its effects on PCO formation in the different groups.
Comparisons between various IOL materials have been done by several authors
during the late 1990s. In 1995, when the eyes included in this study (V) underwent
surgery, experience with various materials was limited. More recently, the presence
of LECs has been found to be lower with polyacrylic than PMMA or silicone IOLs,
and LEC regression occurred more frequently in eyes with polyacrylic IOLs (Hollick
et al. 1998). Polyacrylic IOLs (Ursell et al. 1998, Hollick et al. 1999b), particularly
with sharp-edged (Nagata & Watanabe 1996) optics such as the lens used in the
present study have been shown to be associated with a lower level of PCO. Oner et
al. (2000) reported an incidence for PCO with acrylic lenses to be 8.7% compared
with 24.7% for PMMA lenses after a follow-up of 17.8 + 1.7 months. Acrylic material
possesses high biocompatibility and may enhance adhesion between the capsule
and the IOL (Boulton et al. 1998, Nagata et al. 1998, Oshika et al. 1998,) This `no
space, no cells´ theory is supported by others (Frezzotti & Caporossi 1990, Apple
1992). Linnola (1997) proposed a theory that a highly biocompatible, bioactive
material would allow the remaining LECs to bond both to the IOL and the posterior
capsule.
In the present study, we compared lenses that were commonly used at the
Helsinki University Eye Hospital. At the 2-year control examination, no significant
difference in the frequency of PCO was observed between the 2 groups: 61% of the
eyes in the silicone group and 76% in the acrylic group showed clear posterior
capsules, and 14% in the silicone group and 5% in the acrylic group had mild
central PCO. Clinically significant PCO (serious PCO or capsulotomy performed)
was found in 25% in the silicone group compared with 19% in the acrylic group.
These results are comparable to those of Allers et al. (2000), who found no
significant difference regarding PCO between the same acrylic and silicone lenses.
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Almost half of the eyes in both groups had concurrent ocular diseases, and the
various diseases were rather equally distributed in eyes receiving silicone and
acrylic IOLs. Throughout the series, no significant difference in the formation of
clinically significant PCO was found between eyes with or without concurrent ocular
diseases, but the combination of other ocular disease and silicone IOL appeared to
increase the incidence of PCO. Thus, in eyes with other diseases the prevalence of
clear capsules was significantly lower in the silicone group (31%) than in the acrylic
group (77%), and correspondingly, the incidence of clinically significant PCO was
more frequent in the silicone IOL group (44% vs. 18%, respectively). The number of
eyes with various diseases was too small to allow further comparisons.
In the present series of eyes without other diseases, a clear capsule 2 years after
surgery was observed in 85% in the silicone group and in 73% in the acrylic group.
Apparent clarity of the posterior capsule for up to 2 years after surgery following
polyacrylic lens implantion was also found by Oshika et al. (1996).
In recent studies, capsulotomy rates for acrylic lenses have been low. According to
Hollick et al. (1999b) the capsulotomy rate for polyacrylic lenses was 0% compared
with 26% for PMMA and 14% for silicone IOL. In another study, Hollick et al. (2000)
reported a capsulotomy rate for silicone IOL (Allergan SI30) to be 0% 2 years after
the surgery. In the present study, a total of 4 capsulotomies was performed 2 years
after surgery, 1 in the silicone group in an eye with previous contusion injury and 3
in the acrylic group (1 eye with retinal dystrophy, 1 with POAG and 1 with no
concurrent ocular disease).
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7. SUMMARY
The main results of these 5 articles were:
I
From 1 to 3.6 years after ECCE IOL, IOP decreased significantly both in POAG
and EG eyes, and this decrease was attained with less medication. A total of 58%
of the eyes showed a VA > 0.4, 33% a VA of 0.05-0.3 and 9% were blind. The most
common complication was posterior capsular rupture (6 eyes, 9%).
II
From 0.5 to 3 years after ECCE IOL, IOP and the need for medication decreased
both in ALT- and non-ALT-treated eyes. The decrease in IOP was significant in
ALT-treated eyes. In nonlaser-treated eyes the postitive effect of cataract surgery
on IOP was reflected by decreased glaucoma medication.
III
From 1 to 3.7 years after PHACO IOL, the decrease in IOP in POAG and EG eyes
was highly significant, and the need for medication also decreased. A total of 87%
of the eyes showed a VA > 0.4, 10% a VA 0.05-0.3 and 1 patient (3%) was blind.
Posterior capsular rupture occurred in 1 eye (3%).
IV
In nonglaucomatous EXF and non-EXF eyes, IOP showed a highly significant
decrease 1-2.7 years after PHACO IOL with no significant difference between the
groups. A total of 88% of the eyes showed a VA > 0.4, 10% a VA of 0.05-0.3 and 3
patients (2%) were blind. No serious intraoperative complications occurred.
V
No difference was found in PCO formation between acrylic or silicone IOLs 1-2.4
years after PHACO IOL.
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